FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 609 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR Women Experience More Side Effects from Pelvic Radiation than Realized April 8, 2020 Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,... August 15, 2019 FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin... January 19, 2023 Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline August 28, 2025 Load more HOT NEWS Cancer, COVID-19, and Competing Threats to Indigenous Health Patient Guide in Bladder Cancer Now Available Also in Italian EMA Recommends Extension of Indications for Nivolumab to Include First-Line Treatment... EMA Recommends Granting a Conditional Marketing Authorisation for Sotorasib
